AbbVie Executive Says Now Expect Skyrizi Global Sales Of $11.5B And Rinvoq Sales Of $5.8B This Year
Portfolio Pulse from Benzinga Newsdesk
AbbVie has updated its sales expectations for two of its key drugs, Skyrizi and Rinvoq. The company now anticipates global sales of $11.5 billion for Skyrizi and $5.8 billion for Rinvoq this year.
October 30, 2024 | 1:36 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
AbbVie has increased its sales forecasts for Skyrizi and Rinvoq, indicating strong performance and potential revenue growth.
The increase in sales expectations for Skyrizi and Rinvoq suggests strong market performance and potential revenue growth for AbbVie. This positive outlook is likely to boost investor confidence and could lead to a short-term increase in AbbVie's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100